• Dedicate, Discover, and Develop: Innovation in China to Link the World

    Oct. 18-20, 2014 | Shanghai China

    Join Us Now!
  • Dedicate, Discover, and Develop: Innovation in China to Link the World

    Oct. 18-20, 2014 | Shanghai China

    Join Us Now!
  • Dedicate, Discover, and Develop: Innovation in China to Link the World

    Oct. 18-20, 2014 | Shanghai China

    Join Us Now!

Key Issues

  • Pre-conference workshop: Era Discourses in Clinical R&D of Antibody
  • Keynote Session 1: Speeding up Internationalization-Clinical Development of Antibody
  • Keynote Session 2: Steering the Latest Orientation-Antibody Innovation & Technologies R&D
  • Keynote Session 3: Insights into China’s BioPharma Frontier Policies, Regulations & Markets
  • Keynote Session 4: Seeking Benefits through Cooperation & Investment in BioPharma Market
  • Keynote Session 5: Novel Vaccines Development: Innovations & Applications
  • Keynote Session 6: Exploring vaccine R&D Technologies & Manufacturing
    4th China BioPharma Week-Antibody & Vaccine Focus 2014 is the region’s leading event dedicated to scientific, technology and business development: a strategic keynote conference, real life case studies and interactive roundtables.

Why You Should Attend in 2014?

  • Authoritative Interpreting of Global BioPharma Development Market Trends
  • Forefront of Innovation and New Technology Breakthrough in BioPharma Industry
  • Further Study of the Market Strategy and Technology Application
  • Study to Optimize Antibody & Vaccine Design, Engineering and Production
  • Exploring the Project Cooperation and Investment Opportunity in Asia Especially in China
  • Unique Opportunity of One-on-One Meetings

Don't Just Take Our Word for It:

  • This is a high quality international conference with excellent group of speakers & participants. Very well organized, provided enough opportunity for people to interact. Looking forward to the future events.
    GUO Yajun, Director, Chinese National Engineering Research Centre for Antibody Medicine
  • Excellent conference with great mix of speakers. It provided good platform to learn for scientists who are antibody experts and new in the field. Plenty opportunities to interact with old friends and to meet new ones.
    ZHU Zhenping, EVP, Kadmon Pharmaceuticals
  • This is a very exciting events, with participants from both academia and pharma industry. There is something new for both new-comers to the therapeutics Ab fields and veterans in the industry as well. Great networking opportunities!
    Dr. John L. Xu, Associate Director, Biologics, GSK R&D China
  • Very professionally organized, good questions and knowledgeable topics.
    Dr. Klaus WILGENBUS, Corporate Senior Vice President, Boehringer Ingelheim

4th China BioPharma Convention-Antibody & Vaccine Focus 2014

Biotech drugs have entered the large-scale production stage worldwide. Following the pace, the State Council policy documents have listed the biopharmaceutical as a key development area. It’s expected in 2015 that the volume of China's biopharmaceutical market is expected to reach $100 billion, and antibody drug industry output value will exceed 40 billion. Meanwhile, by the end of 2013, China’s vaccine total production is more than 20 billion RMB, and has steadily grown at an average annual rate of 18%. As the strategic products which are critical to the revitalization of national development, vaccine industry development has been paid much emphasis and stimulated by government powerful policies.

Who You Will Meet:

Battery Manufacturers/ PCS/ Inverter Manufacturers 32%
Energy Storage Projects Owners 22%
Power GridCorp./ Renewable Energy Companies 11%
Electric Power Research Institute10%
Government/ Public Utilities/ Supervision Unit20%
Sales Agency 5%
President, VP,CEO,GM,DGM26%
Chief Scientist, R & D, Registration or Medical Affairs Director / Manager20%
Director/Manager of Technology, Production and Quality Control18%
Director/Manager of Marketing, Project Cooperation and Sales19%
Experts, Professors and Scholars10%

By Industry:

  • Government & Association 5%
  • Big Pharmaceutical 38%
  • Biotechnology Enterprise 10%
  • CRO, CMO 10%
  • Technology and Equipment Provider 20%
  • Academic, College and Scientific Research Institution 8%
  • Third Party Consultation and Investment Institution 6%
  • Others 3%

  Series Media:

Copyright 2004-2013 China Decision Makers Consultancy (CDMC),All rights reserved
T:+86 21 68407631 | F:+86 21 68407632 | E: CBPC@cdmc.org.cn  沪ICP备08011529号